Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18-F flornaptitril - CereMark Pharma

X
Drug Profile

18-F flornaptitril - CereMark Pharma

Alternative Names: [F-18]FDDNP; F-18-flornaptitril; F-18-FNT; F-18-FNT-PET; FDDNP

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles
  • Developer CereMark Pharma
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Brain disorders

Most Recent Events

  • 12 Feb 2024 Phase-II clinical trials in Alzheimer's disease (Diagnosis) (unspecified route) prior to February 2024 (CereMark Pharma pipeline, February 2024)
  • 12 Feb 2024 Phase-II clinical trials in Brain disorders (Diagnosis) (unspecified route) prior to February 2024 (CereMark Pharma pipeline, February 2024)
  • 12 Feb 2024 CereMark Pharma plans a phase III trial for Alzheimer dsease and Chronic traumatic encephalopathy in unknown location (NCT06254469)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top